Department of Neurology, Erasmus MC, Rotterdam, 3015 GE, Netherlands.
Department of Pulmonology, University Medical Center Groningen/University of Groningen, 9713 Groningen, Netherlands.
Proteomics Clin Appl. 2019 Mar;13(2):e1800093. doi: 10.1002/prca.201800093. Epub 2019 Feb 11.
The goal of this manuscript is to explore the role of clinical proteomics for detecting mutations in chronic obstructive pulmonary disease (COPD) and lung cancer by mass spectrometry-based technology. COPD and lung cancer caused by smoke inhalation are most likely linked by challenging the immune system via partly shared pathways. Genome-wide association studies have identified several single nucleotide polymorphisms which predispose an increased susceptibility to COPD and lung cancer. In lung cancer, this leads to coding mutations in the affected tissues, development of neoantigens, and different functionality and abundance of proteins in specific pathways. If a similar reasoning can also be applied in COPD will be discussed. The technology of mass spectrometry has developed into an advanced technology for proteome research detecting mutated peptides or proteins and finding relevant molecular mechanisms that will enable predicting the response to immunotherapy in COPD and lung cancer patients.
本文旨在探讨基于质谱技术的临床蛋白质组学在检测慢性阻塞性肺疾病（COPD）和肺癌突变中的作用。吸入烟雾引起的 COPD 和肺癌很可能通过部分共享途径对免疫系统造成挑战而相关联。全基因组关联研究已经确定了几个单核苷酸多态性，这些多态性使 COPD 和肺癌的易感性增加。在肺癌中，这会导致受影响组织中的编码突变、新抗原的产生，以及特定途径中蛋白质的不同功能和丰度。如果这一推理也适用于 COPD，将进行讨论。质谱技术已经发展成为一种先进的蛋白质组学研究技术，用于检测突变肽或蛋白质，并发现相关的分子机制，从而能够预测 COPD 和肺癌患者对免疫治疗的反应。
